Results 131 to 140 of about 14,687 (252)

Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Children supported with continuous renal replacement therapy have high mortality rates ranging from 30% to 70%. The cause of this high mortality is multifactorial and includes ineffective drug dosing and altered drug pharmacokinetics. Changes in drug exposure can result from (1) underlying disease; and (2) direct drug interaction and/or ...
Autumn M. McKnite, Abdullah Hamadeh, J. Porter Hunt, Danielle J. Green, Carina Imburgia, Aviva Whelan, Rachel Hudson, Andrew Chevalier, Cheryl L. Mathis, Michelle J. Yang, Jamie P. Dwyer, Andrea Edginton, Kevin M. Watt   +12 more
wiley   +1 more source

Modeling and Simulation of Triclosan Kinetics and Distribution in Humans Using a PBPK Model [PDF]

, 2015
Andreassen, Monica, Dirven, Hubert, Husøy, Trine, Lie, Bernt, Maharjan, Samee, Sharma, Roshan   +5 more
core   +6 more sources

Physiologically Based Pharmacokinetic Modeling of Antibiotics in Children: Perspectives on Model-Informed Precision Dosing

Antibiotics
The appropriate use of antibiotics is crucial and involves selecting an optimal dosing regimen based on pharmacokinetic (PK) and pharmacodynamic (PD) indicators.
Ryota Tanaka, Kei Irie, Tomoyuki Mizuno
doaj   +1 more source

Intestinal Organoid‐Based Mathematical Modeling Predicts Clinical Gastrointestinal Toxicity of Oral Oncology Drugs

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Gastrointestinal (GI) toxicity is a common and potentially severe side effect of antiproliferative cancer therapies that often requires dose reduction or treatment interruption. Despite the clinical implications, there are currently no robust strategies for quantitative preclinical assessment of GI toxicity.
Carmen Pin, Deepa Maheshvare M., Louis Gall, Andrew Hall, Muireann Coen, Ambra Bianco, Shimeng Liu, Kenneth Pryde   +7 more
wiley   +1 more source

From Models to Medicines: A Narrative History and Regulatory Perspective on the Translational Impact of Model‐Informed Drug Development (MIDD)

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Model‐informed drug development (MIDD) has grown from a constellation of methodological advances to a profound reorientation of how evidence is generated, evaluated, integrated, and leveraged in both drug development and regulatory decision‐making.
Issam Zineh
wiley   +1 more source

Global Sensitivity Analysis of a Physiologically-based Pharmacokinetic (PBPK) Model of Bromochloromethane [PDF]

, 2020
Sawyer, Colton
core   +1 more source

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) have evolved in the last decade or two from carrying a single chemotherapy payload to carrying highly potent tubulin inhibitors and DNA damaging agents. While the latter have shown success in the clinic, efficacy has been constrained by therapeutic resistance, limited tumor penetration, and suboptimal immune ...
Paulien Ravenstijn, Toru Kakinuma, Salaheldin Hamed, Takeshi Kadokura, Yohei Okada, Srinivasu Poondru   +5 more
wiley   +1 more source

Optimizing Oligonucleotide Therapeutics: A Model‐Informed Drug Development Perspective

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Oligonucleotide therapies have emerged as a powerful therapeutic class, providing novel solutions for diverse diseases through antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers that specifically target and modulate gene expression or protein function. However, oligonucleotide development faces distinct challenges,
Ye Yuan, Vishnu Sharma, Venkatesh Atul Bhattaram, Xiaolei Pan, Justin Earp, Yun Wang, Jiang Liu, Hao Zhu   +7 more
wiley   +1 more source

Advancing Pharmacoequity in Low‐ and Middle‐Income Countries via Model Informed Drug Development

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Across low‐ and middle‐income countries (LMICs) inequities in access to safe, effective medicines persist due to limited regulatory capacity, inadequate financing, and insufficient local data. Regulatory authorities are engaging with model‐informed drug development (MIDD), but uneven technical readiness and resource gaps limit uptake ...
Henry Enzama, Francis Williams Ojara, Ian S. Haworth, Sandra Cvijic, Catriona Waitt, Thaddeus H. Grasela   +5 more
wiley   +1 more source

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Interindividual variability in drug pharmacokinetics and susceptibility to drug–drug interactions remain major barriers in precision dosing, particularly for narrow therapeutic index drugs. While genetic factors contribute, much variability arises from dynamic influences such as physiology, disease, age, diet, microbiome, and concomitant ...
Bhagwat Prasad
wiley   +1 more source